Board of Directors

Doug Cole, MD
Chairman
Doug Cole, MD, has served as a member of our Board of Directors since August 2015. He has been a general partner of Flagship Ventures, where he has focused on life science investments, since 2001. At Flagship, Dr. Cole has led investments in Agios Pharmaceuticals (NASDAQ:AGIO), Alvine Pharmaceuticals, Avedro, CombinatoRx (NASDAQ:ZLCS), Concert Pharmaceuticals (NASDAQ:CNCE), Editas (NASDAQ:EDIT), Quanterix , Receptos (NASDAQ:RCPT), Seventh Sense Biosystems, and Tetraphase Pharmaceuticals (NASDAQ:TTPH). He co-founded Flagship portfolio companies Ensemble Therapeutics, Permeon Biologics, Moderna Therapeutics, and Syros Pharmaceuticals. He currently serves on the Boards of Directors of Agios, Denali, Editas, Ensemble, KSQ, and Quanterix and formerly served on the Board of Directors of Avedro, AVEO Pharmaceuticals (NASDAQ: AVEO), CombinatoRx, Concert, CGI, Moderna, Morphotek, Permeon, Receptos, Resolvyx, Selecta, Seventh Sense, Syros, and Tetraphase. Dr. Cole holds a BA in English from Dartmouth College and an MD from the University of Pennsylvania School of Medicine.

John G. Cox
John G. Cox joined the Torque Board of Directors in January 2019. He is Chief Executive Officer of Torque. He previously was CEO of Bioverativ, leading its spin-out from Biogen in 2016 through its acquisition by Sanofi in 2018. Previously, he held several senior executive positions at Biogen from 2003 to 2016, most recently serving as Executive Vice President of Pharmaceutical Operations and Technology, with responsibility for overseeing Biogen’s global manufacturing facilities, supply chain operations, technical development, quality and engineering, and development and commercialization of Biogen’s biosimilars business. From October 2015 to May 2016, Mr. Cox also served as interim Executive Vice President, Global Therapeutic Operations, responsible for Biogen’s therapeutic groups of Specialty Medicines and Rare Diseases, which included responsibility for the global commercial performance of Biogen’s marketed products. His additional positions with Biogen included Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, and Vice President of Manufacturing and General Manager of Biogen’s operations in Research Triangle Park, North Carolina. Mr. Cox received a BS in Cell Biology from California State University and an MBA in Finance from the University of Michigan.

John M. Dineen
John M. Dineen has served as a member of our Board of Directors since January 2016. He is an Operating Advisor to Clayton, Dublier & Rice, LLC, a private equity firm based in New York. Mr. Dineen serves as the Chairman of Healogics Corp and is a member of the board of directors of Merrimack (NASDAQ:MACK). From 1986 to 2015, Mr. Dineen served in a variety of leadership roles in the U.S., Europe, and Asia with the GE Company. During his tenure at GE, he served as President and Chief Executive Officer of GE Healthcare, Chief Executive Officer of GE Transportation, President of GE Plastics, General Manager of GE’s Power Equipment business, and General Manager of GE Appliance’s, Microwave and Air-Conditioning businesses. He holds BS degrees in Biology and Computer Science from the University of Vermont.

John A. Hohneker, MD
John Hohneker, MD, has served as a member of of our Board of Directors since March 2018. He is President and CEO of Anokion, a privately held, discovery-stage biotechnology company. Prior to joining Anokion, he was President of Research and Development at FORMA Therapeutics, where he led multiple programs into clinical trials. Dr. Hohneker also held several leadership positions at Novartis, including Senior Vice President and Global Head of Development for Immunology and Dermatology. At Novartis, Dr. Hohneker played a key role in the development, approval, and commercialization of products that include Cosentyx®, Xolair®, Ilaris®, Gleevec®, Tasigna®, Zometa®, Afinitor®, and Exjade®. Prior to joining Novartis, he held positions of increasing responsibility at Glaxo Wellcome and its legacy company, Burroughs Wellcome. Dr. Hohneker served on the Board of Directors for Dimension Therapeutics prior to its acquisition by Ultragenyx Pharmaceutical (NASDAQ: RARE). He received a bachelor’s degree in Chemistry from Gettysburg College and an MD from the University of Medicine and Dentistry of New Jersey at Rutgers Medical School, and he completed his internship and residency in internal medicine and his fellowship in medical oncology at the University of North Carolina Hospitals.

Doug Lauffenburger, PhD
Doug Lauffenburger, PhD, has served as a member of our Board of Directors since January 2016. He is the head of the Department of Biological Engineering at the Massachusetts Institute of Technology and a pioneer in applying engineering principles to biological research. His expertise spans multiple disciplines including chemical engineering, bioengineering, biotechnology process engineering, biophysics, quantitative cell and structural biology, systems biology, and applied mathematics. He has filed numerous patents, authored a key textbook on receptor biology, and published more than 200 peer-reviewed articles. Dr. Lauffenburger is a member of the National Academy of Engineering and has served on numerous bio/pharma industry scientific advisory boards including Pfizer, Astra-Zeneca, Eli Lilly, Johnson & Johnson, and Merrimack. Dr. Lauffenburger received a BS in Chemical Engineering from the University of Illinois and a PhD in Chemical Engineering from the University of Minnesota.

Maykin Ho
Strategic Advisor
Maykin Ho was appointed as a strategic advisor to the Torque Board of Directors in July 2018. Dr. Ho is a member of the board of directors of Agios Pharmaceuticals, PAREXEL International, the Institute for Protein Innovation, and the Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University. She is also a venture partner at Qiming Venture Partners. Dr. Ho is a retired Partner of Goldman Sachs & Co., where she was most recently Advisory Director for Global Healthcare Investment Banking during her 23-year tenure with the firm. Previously, she was the lead biotechnology analyst and co-Head of U.S. Healthcare for Global Investment Research. Dr. Ho was ranked the First or Second Team in Biotechnology by Institutional Investor and Greenwich Associates for more than 10 years. She has also received numerous awards from The Wall Street Journal and Financial Times. Prior to joining Goldman Sachs, Dr. Ho held senior management positions in research, marketing, and business development at Dupont-Merck Pharmaceuticals and Dupont De Nemours & Company. She was a postdoctoral fellow at Harvard Medical School and a graduate of the Advanced Management Program of the Fuqua School of Business at Duke University. Dr. Ho received a PhD in Microbiology and Immunology and a BS from the State University of New York, Downstate Medical Center.

Back to Top